Synergistic immunosuppression caused by high-dose methylprednisolone and cardiopulmonary bypass

Annals of Thoracic Surgery

Volumn 63, Issue 1, 1997, Pages 129-137

  Mayumi, Hisanori ^a   Zhang, Qui Wei ^a   Nakashima, Atsuhiro ^a   Masuda, Munetaka ^a   Kohno, Hiroyuki ^a   Kawachi, Yoshito ^a   Yasui, Hisataka ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; INTERLEUKIN 2; LACTIC ACID; LYMPHOCYTE SURFACE MARKER; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE TOLERANCE; HEART OUTPUT; HEART VALVE REGURGITATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LYMPHOCYTE FUNCTION; MALE; POSTPERFUSION SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE;

ANTIGENS, SURFACE; B-LYMPHOCYTES; C-REACTIVE PROTEIN; CARDIOPULMONARY BYPASS; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HEART VALVE PROSTHESIS; HUMANS; IMMUNOCOMPROMISED HOST; INTERLEUKIN-2; KILLER CELLS, NATURAL; MALE; METHYLPREDNISOLONE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 0031018951     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(96)00682-0     Document Type: Article

References (28)

1. Weil MH, Whigham H. Corticosteroid for reversal of hemorrhagic shock in rats. Am J Physiol. 209:1965;815-818.
2. Dietzman RH, Castaneda AR, Lillehei CW, Ersek RA, Motsay GJ, Lillehei RC. Corticosteroids as effective vasodilators in the treatment of low output syndrome. Chest. 57:1970;440-453.
3. Hammerschmidt DE, Stroncek DF, Bowers TK, et al. Complement activation and neutropenia during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 81:1981;370-377.
4. Tennenberg SD, Bailey WW, Cotta LA, Brodt JK, Solomkin JS. The effects of methylprednisolone on complement-mediated neutrophil activation during cardiopulmonary bypass. Surgery. 100:1986;134-142.
5. Jansen NJG, van Oeveren W, Broek LVD, et al. Inhibition by dexamethasone of the reperfusion phenomena in cardiopulmonary bypass. J Thorac Cardiovasc Surg. 102:1991;515-525.
6. Almdahl SM, Waage A, Ivert T, Vaage J. Release of bioactive interleukin 6 but not of tumour necrosis factor-α after elective cardiopulmonary bypass. Perfusion. 8:1993;233-238.
7. Miranda DR, Stoutenbeek C, Karliczek G, Rating W. Effects of dexamethasone on the early postoperative course after coronary artery bypass surgery. Thorac Cardiovasc Surg. 30:1982;21-27.
8. Roth JA, Golub SH, Cukingnan RA, Brazier J, Morton DL. Cell-mediated immunity is depressed following cardiopulmonary bypass. Ann Thorac Surg. 31:1981;350-356.
9. Hisatomi K, Isomura T, Kawara T, et al. Changes in lymphocyte subsets, mitogen responsiveness, and interleukin-2 production after cardiac operations. J Thorac Cardiovasc Surg. 98:1989;580-591.
10. Snyder DS, Unanue ER. Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production. J Immunol. 129:1982;1803-1805.
11. Verbruggen G, Herman L, Ackerman C, Mielants H, Veys EM. The effect of low doses of prednisolone on T-cell subsets in rheumatoid arthritis. Int J Immunopharmacol. 9:1987;61-67.
12. Piccolella E, Lombardi G, Vismara D, et al. Effects of dexamethasone on human natural killer cell cytotoxicity, interferon production, and interleukin-2 receptor expression induced by microbial antigens. Infect Immunol. 51:1986;712-714.
13. Knudsen F, Andersen LW. Immunological aspects of cardiopulmonary bypass. J Cardiothorac Anesth. 4:1990;245-258.
14. Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 55:1993;552-559.
15. Michler RE, Chen JM, Mancini DM, Reemtsma K, Rose EA. Sixteen years of cardiac transplantation the Columbia Presbyterian Medical Center experience 1977 to 1993 . Terasaki PI, Cecka JM. Clinical transplants 1993. 1993;109-118 UCLA Tissue Typing Laboratory, Los Angeles.
16. Mayumi H, Matsui K, Matsuzaki K, Uchida T, Shinozaki K, Tokunaga K. Cellular kinetics of posttransfusion graft-versus-host disease after heart operations. J Thorac Cardiovasc Surg. 108:1994;179-182.
17. Mayumi H, Kawachi Y, Matsuzaki K, Tanoue S, Yasui H. Positive correlation between pericardial effusion and wound infection following open-heart surgery. Cardiovasc Surg (in press).
18. Juji T, Takahashi K, Shibata Y, et al. Post-transfusion graft-versus-host disease in immunocompetent patients after cardiac surgery in Japan [Letter]. N Engl J Med. 321:1989;56.
19. Kinoshita K, Oe M, Tokunaga K. Superior protective effect of low-calcium, magnesium free potassium cardioplegic solution on ischemic myocardium: clinical study in comparison with St. Thomas' Hospital solution. J Thorac Cardiovasc Surg. 101:1991;695-702.
20. Mayumi H, Good RA. Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance inducing method using cyclophosphamide. J Exp Med. 169:1989;213-238.
21. + T cells in cyclophosphamide- induced tolerance to H-2 compatible, Mls-disparate antigens. J Exp Med. 171:1990;97-113.
22. Tajima K, Yamamoto F, Kawazoe K, et al. Cardiopulmonary bypass and cellular immunity changes in lymphocyte subsets and natural killer cell activity . Ann Thorac Surg. 55:1993;625-630.
23. Shaw AR, Bleackley RC, Merryweather JP, Barr PJ. Modulation of human natural killer cell activity by recombinant human interleukin 2. Cell Immunol. 90:1985;547-554.
24. Tønnesen E, Wahlgreen C. Influence of extradural and general anaesthesia on natural killer cell activity and lymphocyte subpopulations in patients undergoing hysterectomy. Br J Anaesth. 60:1988;500-507.
25. Tønnesen E, Brinkløv MM, Olesen AS, Christensen NJ. Natural killer cell activity in a patient undergoing open-heart surgery complicated by an acute myocardial infarction. Acta Path Microbiol Immunol Scand. 93:1985;229-231.
26. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 170:1989;827-845.
27. Bass DA, Parce JW, Dechatelet LR, Szejda P, Seeds MC, Thomas M. Flow cytometric studies of oxidative product formation by neutrophils a graded response to membrane stimulation . J Immunol. 130:1983;1910-1917.
28. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 317:1987;653-658.